The Daily

Greg Brockman's courtroom testimony puts a human number on OpenAI's restructuring fight: his personal stake is now valued near $30bn. The useful story is governance, not trial color. Musk's suit asks the court to unwind the for-profit move, remove Brockman and Sam Altman, and slow OpenAI's path toward a much larger IPO story.

Monday night brought two second-round Game 1s: 76ers-Knicks and Timberwolves-Spurs. Both sit inside Robert's spoiler window, so this stays to matchups and viewing priority only. Wikihoops gives Spurs-Wolves the stronger replay signal; Knicks-Sixers is the completist opener, with no scores, winners, stats or updated series state here.

Boehringer Ingelheim is warning that Europe risks yielding pharma innovation to the US and China if pricing and reimbursement rules stay slow. Hernexeos is the concrete case: a lung-cancer drug invented in Europe has launched in the US, China and Japan while European access waits on reimbursement and comparator-trial demands. The strategic issue is whether Europe can reward domestic invention before companies learn to launch elsewhere first.

A Nature Medicine phase 1 study generated anti-BCMA CAR-T cells inside patients with relapsed or refractory multiple myeloma. The early value is feasibility: in-vivo generation could bypass ex-vivo manufacturing and lymphodepletion. The caution is equally important, because the dataset is only five patients and belongs in the proof-of-concept bucket.

Surreale Gärten - vier Kunstorte in Italien
Nutzwert - Umwege statt Standard-Checkliste
Timing - aktueller NYT-Travel-Guide vom 04.05.2026

Für Roberts Italien-Fokus ist das stark, weil es nicht noch einmal Rom, Venedig oder Amalfi sortiert. Es sind Orte, die eine Route persönlicher machen, ohne gleich eine ganze Reise umzubauen.